YaoTang Biotechnology and XtalPi have officially declared a partnership aimed at propelling the groundbreaking progress of artificial intelligence (AI)-aided messenger ribonucleic acid (mRNA) drug innovation. The collaboration will center on the domains of mRNA drugs and CAR-T therapy, with both entities collaborating to construct an AI-driven closed-loop screening platform tailored for both wet and dry mRNA experiments. This platform will seamlessly blend the capabilities of XtalPi's AI models with YaoTang Biotechnology's profound expertise in mRNA drugs and gene editing, with the overarching goal of boosting the efficiency and success rate of mRNA drug development.
The platform is designed not only to cater to the demands of current specific target projects but also to possess the flexibility to scale up and address more intricate disease application scenarios. Both YaoTang Biotechnology and XtalPi are optimistic that this partnership will pave the way for a revolutionary approach to mRNA drug development, expedite the practical application of mRNA molecules, and ultimately furnish patients across the globe with a wider array of innovative treatment options.